The rising frequency of cardiovascular and respiratory illnesses, as well as industrial partnerships by major market players, are projected to propel the extracorporeal membrane oxygenation system market forward.
The primary challenges impeding the growth of the worldwide extracorporeal membrane oxygenation system market are ECMO system issues such as internal bleeding, blood clotting, or technical failure, as well as the high cost of ECMO equipment.
ALung Devices, Inc., the leading developer of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, was bought by LivaNova PLC, a worldwide medical technology business, in May 2022.
Global Extracorporeal Membrane Oxygenation System Market
According to Coherent Market Insights, is estimated to be valued at US$ 316.5 million in 2022 and is expected to exhibit a CAGR of 5.3% during the forecast period (2022-2030).
Leading Companies in the Extracorporeal Membrane Oxygenation System Industry:
1. Medtronic
The company was founded in 1949 and is headquartered in Dublin, Ireland. Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. On August 30, 2022 Medtronic plc announced that it has completed the acquisition of Affera, Inc. This acquisition expands the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution.
2. Getinge AB
The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden. It offers products thorugh distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. On April 27, 2022, Getinge announced an agreement to acquire FLUOPTICS SAS, a French based leader in fluorescence imaging as an aid to surgery.
3. LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom. On December 2022, LivaNova PLC Acquires ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure.
